The port delivery system with ranibizumab (PDS) is in clinical development for the treatment of
diabetic macular oedema (DMO). DMO is swelling of the macula caused by diabetes or by
blockage of the veins behind the retina and it is the most common cause of sight loss in people
with diabetes. DMO occurs when blood vessels damaged by high blood sugar leak into the
central area of the retina (macular) resulting in a fluid build-up.
Ranibizumab port delivery system for treating
diabetic macular oedema
The port delivery system with ranibizumab (PDS) is in clinical development for the treatment of diabetic macular oedema (DMO).
Interventions:
Ranibizumab (Lucentis Port Delivery System; Lucentis)
Indications:
Diabetic macular oedema
Year:
2022